


# Fast, Affordable & Convenient !



## FDA-Approved Drug Library Mini (96-well plate, 10 $\mu$ L/well)

Cat. No. : HY-L022M


### Introduction :

FDA-Approved Drug Library is a useful tool that allows researchers to discover novel targets of old drugs and to find new functions of the known targets. The FDA-Approved Drug Library Mini is designed with a smaller size (10  $\mu$ L) and simplified packaging (96-well microplate with peelable foil seal) for research convenience.

### Advantages :

1. Easily peelable foil seal makes the screening process easier and faster.
2. Lower price, more compounds.
3. Avoid multiple and uneven dispensing.
4. Reduce risks of product cross-contamination.
5. Avoid reduced activity due to long-term storage.

#### FDA-Approved Drug Library Mini



<b>Size</b>	10 $\mu$ L in DMSO
<b>Package</b>	96-well microplate with peelable foil seal
<b>Delivery Date</b>	Within three days
<b>Price Per Set</b>	Low
<b>Preparation For Use</b>	Tear off the seal film on the microplate

#### FDA-Approved Drug Library (Cat. No. : HY-L022)



<b>Size</b>	30, 50, 100, and 250 $\mu$ L in DMSO
<b>Package</b>	96-Well Format Sample Storage Tube With Screw Cap
<b>Delivery Date</b>	About one month
<b>Price Per Set</b>	High
<b>Preparation For Use</b>	If there is no robot, each tube needs to be manually opened

MedChemExpress LLC

Tel: 609-228-6898

E-mail: [sales@MedChemExpress.com](mailto:sales@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

# Small Molecule Immuno-Oncology Compound Library

Cat. No. : HY-L031



Immuno-Oncology is an innovative approach that uses the body's immune system to help fight cancer.

In 2018, two Immuno-oncology scientists won the **Nobel Prize in Physiology or Medicine** for their discovery of cancer therapy by inhibition of negative immune regulation.

Though most of these breakthrough medicines in immuno-oncology are monoclonal antibodies that block protein-protein interactions, **small-molecule immunotherapy** brings bright prospects to cancer treatment. Compare with therapeutic antibodies, small molecule immuno-oncology agents usually have **better oral bioavailability, higher tissue and tumor penetration, reasonable half-lives**, etc.

**MCE small molecule immuno-oncology screening compounds** target a wide variety of proteins/receptors that may be useful in the cancer immunotherapy, such as PD1/PD-L1, RORyt, Chemokine receptor, STING, IDO, TLR, etc.




Figure 1. Potential targets for small molecules in cancer immunotherapy.

Target	PD1/PD-L1	RORyt	Chemokine Receptor	STING	IDO	TLR
Effect Type	Inhibitor	Agonist	Antagonist	Agonist	Inhibitor	Agonist
Mechanism of Small Molecules	Decrease Immune Suppression	Increase Immune Activation	Decrease Immune Suppression	Increase Immune Activation	Decrease Immune Suppression	Increase Immune Activation
Targeted Immune System	Adaptive	Adaptive	Adaptive	Innate	Tumor microenvironment	Innate

## References:

McNutt M, Cancer immunotherapy. Science. 2013 Dec 20;342(6165):1417.

Cheng B et al., Recent advances in small molecule based cancer immunotherapy. Eur J Med Chem. 2018 Sep 5;157:582-598.

Inhibitors • Agonists • Screening Libraries

[www.MedChemExpress.com](http://www.MedChemExpress.com)

